People
The People
Zoetis earns a governance grade of B+ — independent, well-credentialed board with clean disclosure and a coordinated wave of director buying after the May 2026 stock crash, partially offset by thin insider ownership, an opportunistic-looking CEO sale weeks before the cut to guidance, and a freshly opened plaintiff-lawyer fishing expedition.
Governance Grade
Skin-in-Game (/10)
Insiders + Directors Own
The People Running This Company
A small, durable executive bench led by a six-year-tenured CEO who was inside Zoetis from spin-off, paired with a CFO recruited externally during the post-Covid demand surge. The 2024–2025 reorganization promoted Jamie Brannan to a newly created Chief Commercial Officer role and lined up Kevin Esch to succeed retiring R&D head Robert Polzer — a planned succession, not a scramble.
Peck is the legitimate animal-health operator the spin needed — she ran Worldwide Business Development at Pfizer when Zoetis was carved out and has run the company since Juan Ramón Alaix retired. The most consequential 2025 personnel call was creating a global CCO role for Brannan; if Q1 2026's pet-owner price-sensitivity problem persists, this is where the accountability lives. Polzer's retirement was disclosed in advance and Esch is an internal R&D promotion, so the pipeline narrative the bull case rests on is not being handed to an outsider mid-stride.
What They Get Paid
CEO TDC of $19.05M in 2025 is in line with large-cap pharma peers but the mix matters more than the dollar: 92% is at-risk, 80% of target is long-term equity, and the performance-share units have three-year cliffs against relative TSR and operational revenue growth. The $1.49M "All Other" line for Peck is essentially mandatory personal security and private-aircraft use ordered by the Board after an independent third-party study — not a discretionary perk.
The 2025 jump in Peck's "Other" line ($427K → $1,885K) is almost entirely the $1.49M of board-mandated personal security and private-aircraft costs added after an independent threat assessment — not a lifestyle perk, but worth flagging because shareholders fund it regardless.
Shareholders approved the 2024 program with 91% Say-on-Pay support at the 2025 AGM. That is solid but not exceptional — 5–10 points below the best-governed peers — and signals some institutional pushback on either the target-setting or the size of the LTI grant.
Are They Aligned?
The single most important governance fact about Zoetis: directors and the entire 22-person executive group own less than 1% of the company combined (912,848 shares of 420.6M outstanding). This is a hired-management, institution-controlled stock. The two largest holders are Vanguard and BlackRock with a combined ~20% — both passive, both vote with ISS more often than with management.
Ownership and control
CEO Peck personally holds 105,902 shares plus 386,684 vested options (total 492,586) — worth roughly $37M at recent prices, or about 2× her annual target TDC. That clears the company's NEO ownership guideline (a multiple of base salary) but is not "skin in the game" by founder/owner-operator standards.
Insider behavior — the May 2026 signal
Green flag. Three independent directors — including Board Chair McCallister and two ex-CFO directors (D'Amelio of Pfizer, Bisaro of Amneal) — bought a combined ~$886K of stock in the open market in the six trading days after the May 7, 2026 guidance cut and 21.5% single-day drop. Coordinated director buying at the bottom is the loudest insider signal there is.
Yellow flag. On Feb 17, 2026 CEO Peck exercised 20,000 options at $41.83 and sold the resulting shares at $126–128, netting ~$1.7M of pre-tax profit. The May 7 guidance cut took the stock to $77. The sale was almost certainly under a pre-set 10b5-1 plan, but the optics — selling at the highs eleven weeks before a guidance cut she had to know was developing — sit awkwardly with the new plaintiff-lawyer investigations.
Capital allocation behavior
The company returned $4.12B to shareholders in 2025 ($889M dividends + $3,235M buybacks) — actually above 2025 reported net income. Funding included a $1.75B 0.25% convertible note paired with a capped call to enable a $1.3B repurchase while limiting dilution. Quarterly dividend was raised 6% in December 2025. Share count has been declining; SBC is modest for the sector.
Related-party transactions
Per the 2026 proxy: "There are no relationships or transactions with related persons during fiscal year 2025 that are required to be disclosed." Clean.
Skin-in-the-game score: 5/10
Below average in absolute insider stake (<1% combined), but pulled up by (a) very high at-risk pay mix, (b) the May 2026 director buying, (c) compliant ownership-guideline enforcement, and (d) the absence of related-party or pledging concerns. A founder-led comparable would score 8–9; a heavily-pledged controlled company would score 2–3. Zoetis is a normal large-cap with a recently well-aligned board.
Board Quality
Twelve directors after Louise Parent retires at the 2026 AGM; eleven are independent under NYSE standards, with CEO Peck the only insider. The board is heavy on big-pharma CFOs (Norden ex-Wyeth, D'Amelio ex-Pfizer), veterinary academia (Reed of Purdue, Stetter of UC Davis), and consumer/marketing operators (Khosla ex-Mondelēz, Hattersley of Molson Coors, Broadhurst of J&J). All four committees are 100% independent.
Three points stand out:
- Veterinary depth is real, not cosmetic. Reed (Purdue) and Stetter (UC Davis) chair or sit on the Quality & Innovation Committee and bring genuine clinical/scientific expertise — exactly what is needed to challenge the pipeline narrative.
- Heavy ex-CFO presence on Audit. Three of six Audit members (Norden, D'Amelio, Hattersley) qualify as "audit committee financial experts" — strongest possible composition.
- Tilenius brings digital health/AI (founded Vida Health, Peak Health; also a BlackRock director) — important given Zoetis's stated AI/diagnostics pivot.
What's weak
The real watch-item is board age and tenure. Five of the longest-serving directors are 68–74 years old and will time out of the seven-year retirement cliff within this CEO's expected remaining tenure. The Corporate Governance Committee has acknowledged this — four new independents added in four years (Hattersley 2024, Broadhurst 2022, Leatherberry 2020, plus Stetter and Tilenius in 2025) — and refreshment is described as a stated multi-year priority. The plan is real, but execution risk is real too.
The Verdict
Governance grade: B+
The one thing that would change the grade: The pending securities fraud investigation is the swing factor. If it produces evidence that management saw the Q1 demand softness materially before the Peck sale window closed in mid-February — or that AIP / PSU goals were being engineered around it — the grade falls to a C quickly. Conversely, if Q2 2026 stabilises the demand picture and directors keep buying through summer, the optics flip and this becomes an unambiguous A-.